Medindia LOGIN REGISTER
Medindia

Game-Changing Solution for Oral Health: Adhesive Patch

by Karishma Abhishek on Mar 19 2023 5:27 PM
Listen to this article
0:00/0:00

New study highlights the development of an innovative adhesive patch capable of treating two common oral health disorders.

Game-Changing Solution for Oral Health: Adhesive Patch
Scientists have created a groundbreaking novel bioinspired adhesive patch, “Dental Tough Adhesive (DenTAI)” with robust mechanical properties for the treatment of common oral health disorders.
The strong adhesive patch is capable of extended release of clobetasol-17-propionate, the first-line drug for treating oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS).

The study was presented at the 52nd Annual Meeting & Exhibition of the AADOCR, held in conjunction with the 47th Annual Meeting of the CADR. The AADOCR/CADR Annual Meeting & Exhibition took place at the Oregon Convention Center in Portland on March 15-18, 2023.

This research was presented as part of the Interactive Talk presentation, “Tough Adhesive Hydrogel for Intraoral Drug Delivery”.

The study, led by David T. Wu of the Harvard University School of Dental Medicine, characterized ex vivo adhesion to diverse oral tissues (tongue, lip, gingiva, buccal mucosa) with mechanical testing. In vitro cytotoxicity was examined with WST cell viability assay on primary human gingival epithelial cells cultured in DenTAl-conditioned media.

New Hope for Oral Health Disorders

Clobetasol-17-propionate release was assessed with liquid chromatography-mass spectrometry (LC-MS). In vitro immunomodulation assay was performed.

DenTAl were found to have superior physical and adhesive properties compared to existing oral technologies, with ~2-100x adhesion (up to 1600 J/m2) to oral tissues and ~3-15x stretchability.

Advertisement
Clobetasol-17-propionate incorporated into the DenTAl was released in a tunable sustained manner over weeks and demonstrated immunomodulatory capabilities in vitro, evidenced by reductions in several cytokines including TNF-a, IL6, IL10, MCP5, MIP-2, and TIMP-1.

The study’s findings suggested that DenTAl may be a promising device for intraoral delivery of small molecule drugs applicable to the management of painful oral lesions associated with inflammatory conditions such as OLP and RAS.

Advertisement
Source-Eurekalert


Advertisement